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METHOD
Materials. All chemicals and media used in this study, including buffers and salts were of the high analytical grade (>98%). Compounds 1 and 2 were synthesized as previously described with purity >95 %. 1 The biotin labeling kit, 3,3'-5,5'-tetramethylbenzidine (TMB), and Streptavidin HRP Conjugate were purchased from Roche.
Gene Expression and Protein Purification. To express the PfMIF gene, the full length nucleotide sequence was optimized for expression in E. coli, cloned into the pCRT7 expression vector (Invitrogen), and expressed using BL21(DE3) E. coli cells. Briefly, the cells were grown to an O.D. of 600 nm of 0.6 and induced using 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 37°C. After 4 h, the cells were harvested and resuspended into lysis buffer (20 mM Tris-HCl, pH 8.0, 20 mM NaCl), supplemented with an EDTA-free protease inhibitor tablet, and lysed with sonication. The cell lysate was filtered and loaded onto a QSepharose column (120 ml). The protein was eluted with a linear pH gradient from pH 8.0 in the lysis buffer to pH 6.8 in a buffer containing 30 mM Bis-Tris and 20 mM NaCl. The buffer was exchanged into lysis buffer and reloaded onto the Q-Sepharose column for salt gradient purification (from 20 mM to 1M NaCl in 20 mM Tris-HCl, pH 8.0). Pure PfMIF (>95 %) eluted at ~0.6-0.7 M NaCl. To remove other contaminants, PfMIF was exchanged into lysis buffer, loaded onto an SP-Sepharose column, and eluted in the flow-through. The pure PfMIF was concentrated using Amicon Ultra Centrifugal filter units with a 10,000 molecular weight cut-off.
For expression of the extracellular domain of CD74 (his) 6
114-232 , the gene was cloned into the pET28a vector (Novagen) and expressed in BL21 (DE3) E. coli cells. The cell were grown at 37°C until the O.D. of 600 nm was 0.6 and induced with 0.4 mM of IPTG for 5 hours at 30 °C. The cells were resuspended into 20 mM Tris-HCl, 20 mM NaCl, 20 mM imidazole, pH 7.4, and lysed. The cell lysate was loaded onto a 5 ml HisTrap column (GE Healthcare). The pure protein (>95 %) was eluted using a gradient of 0-500 mM imidazole.
For expression of hMIF, pET11b-MIF expression vector was used as described previously. 2 The cells were resuspended into 20 mM Tris-HCl, pH 7.4, and 20 mM NaCl, and lysed by sonication. The cell lysate was loaded onto a Q-Sepharose column connected in series to a SP-Sepharose column and the protein was eluted as the flow-through product. Small amounts of contaminants (~5%) were removed with Superdex 75 (size exclusion).
Crystallization and Structure Determination. To identify crystallization conditions, PfMIF was concentrated to 18 mg/ml and mixed with compound 1 or 2 at 1:3 MIF trimer:compound molar ratio followed by overnight incubation at 4°C. The next day each protein-inhibitor complex was centrifuged at 20 x g for 5 min and mixed with crystallization screening solutions (Hampton Research) at 1:1 ratio. The mixture was transferred to a 96-well round bottom COSTAR plate (Number 3795) with UV transparent plate seals. The whole procedure was carried out with a Mosquito (TTP LabTech) liquid handing robot. Each well contained 100 µl of crystallization condition. The plates were stored in a Rock Imager 1000 at 20°C and the drops were monitored on a regular basis. After the period of 8 days, crystals appeared in two crystallization conditions: i) 0.1 M Hepes, pH 7.5, 2M ammonium sulfate, 2% v/v PEG 400 (HR2-110), and ii) 0.1 M Hepes, pH 7.5, 1.0 M sodium citrate tribasic dehydrate (HR2-114). Due to poor diffraction, the crystallization conditions were optimized further. The 1:3 complex at 10 mg/ml of MIF was mixed with equal volumes of a well solution that contained 0.1 M Hepes
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or Tris-HCl buffer pH 7.0-8.5, 2 M ammonium sulfate, and specific additives from the additive screening set (Hampton Research). Good quality crystals were grown via the hanging drop vapor diffusion method in a 24-well plate with 0.1 M Tris-HCl, pH 8.0, 2 M ammonium sulfate, 0.1 M NaCl. The crystals were flash frozen in the mother liquor containing 3.6 M ammonium sulfate as a cryoprotectant. The data sets were collected at the Yale School of Medicine Macromolecular Facility using a R-AXIS IV++ image plate detector (Rigaku, Tokyo, Japan) with a Rigaku rotating copper anode X-ray generator at -180°C, integrated, and scaled with HKL-2000. The PfMIF complexes with 1 and 2 diffracted to 3.02 Å and 2.87 Å in space group I222, respectively. The models of the PfMIF inhibitor complexes were solved by molecular replacement using PHASER. For PfMIF complexed to compound 1, the structure of Plasmodium berghei (Pb) MIF (PDB entry 2WKB) was used as the search model. The PfMIF complexed to compound 2 was solved with the protein coordinates from the PfMIF-compound 1 complex (without inhibitor) as the search model. Density modification was carried out with PARROT (CCP4) and refinement with REFMAC and COOT. Atomic models of the inhibitors were produced by the PRODRG server, fitted in electron density using COOT, and refined. The Fo-Fc maps of the compounds were generated by FFT (CCP4) and visualized in PyMOL. Interactions between PfMIF and the two compounds were calculated and visualized using CONTACTS (CCP4), LIGPLUS, and PyMOL. Hydrophobic interaction between the active site residues and compounds 1 and 2 were illustrated using LIGPLUS. The structures of apo-PfMIF (PDB entry 2WKF) and hMIF (PDB entry 3DJH) were superimposed using SUPERPOSE (CCP4). The electrostatic potential of PfMIF and hMIF was calculated PyMOL.
Soluble CD74 (his) 6
114-232 capture assay. Soluble CD74
(his) 6
114-232 in PBS was used to coat a 96-well ELISA plate at a concentration of 26 ng/µl. After overnight incubation and washing with PBS/0.1% buffer Tween-20 (PBS-T), the plate was blocked with Superblock (Pierce) for 2 hours at room temperature. Recombinant PfMIF or hMIF was biotinylated using a Biotin labeling kit (Roche). Biotinylated-PfMIF or biotinylated-hMIF at a concentration of 5 ng/µl was incubated with increasing concentrations of compounds 1 and 2 (0.1, 0.25, 0.5, and 2.5 µM) or DMSO as vehicle control for 45 min with shaking at room temperature. After 45 min, the biotinylated sample (PfMIF-inhibitor complex or hMIF with inhibitor) was added to the plate and incubated overnight at 4°C. The next day the plate was washed with PBS-T, conjugated with Streptavidin HRP (Roche), and incubated at room temperature for one hour. After washing with PBS-T, the peroxidase substrate 3,3'-5,5'-tetramethylbenzidine (TMB, from Roche) was added and the plate was incubated for 20 min. The reaction was terminated with 1N H 2 SO 4 /HCl. The results were expressed as the percentage of binding in the presence of compounds 1 or 2 compared with binding in the absence of inhibitors.
Molecular Docking. The graphical user interface Maestro (version 9.8, Schrödinger, LLC, New York, NY, 2014) provided through the Structural Biology Grid 3 was used to access all of Schrödinger's computational programs, including Glide 4-6 (version 6.3, Schrödinger, LLC, New York, NY, 2014) implemented herein for docking. Docking was performed in successive standard precision (SP) and extra precision (XP) modes in Glide. Input protein and ligand structures used for docking were derived from their respective co-crystal structures, and prepared using Schrödinger's Protein Preparation Wizard 7 and LigPrep 8 tools, respectively. Flexible ligand conformations were sampled while fixing the receptor to a single, rigid conformation. The selection of initial poses kept 50,000 poses per ligand within a scoring window of 100 kcal/mol, but only the best 1000 poses per ligand were subject to energy minimization, which consisted of 250 minimization steps at a distance-dependent dielectric constant of 2. All van der Waals radii were scaled down by a factor of 0.8 for partial charges <0.15 in ligand atoms. In SP mode, a maximum of 500 poses were generated per input ligand, and a maximum of 1 pose was generated in XP mode from each SP-derived pose. Final poses were scored by Schrödinger's GlideScore and model energy (E-model) scoring functions. Taking into consideration differences in residue environment between the three active sites of co-crystallized Pf MIF, each prepared ligand was docked exclusively within the protein structure and active site from which the ligand was derived. As such, receptor grid generation was performed by confining the central coordinates of each native ligand within an enclosing box having side lengths of 20 Å. Of note, native ligands were automatically excluded from the grid generation step to prevent occupancy bias in the docking. Poses for a given ligand entry were ranked and evaluated according to their E-model scores. Furthermore, as a quantitative measure of docking accuracy, RMSD calculations were performed in the docking step to measure heavy-atom displacements between generated poses and their corresponding native ligands in the crystal structure. All output poses were saved and documented, but only poses within an RMSD cutoff of 2 Å were deemed to be consistent with the co-crystal.
Temperature-dependent circular dichroism (CD) study. The samples were prepared in 20mM Tris, pH 8.0, and 20 mM NaCl at a concentration of 50 µg/ml. CD data were recorded using a Chirascan Applied Photophysics spectrometer with thermoelectric temperature control.
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Supplementary Figure S1 . Alignment of PfMIF protein sequences. Comparison between the apoPfMIF (2WKF) and PfMIF-inhibitor complexes (4P7M and 4P7S) revealed that the latter possess more C-terminal residues, especially in chain A. The missing residues are highlighted in grey.
(*Chain C was not part of the asymmetric unit of the apo-PfMIF, which forms a trimer by crystallographic symmetry with an adjacent subunit. Therefore, it was not possible to compare the missing residues of this chain.). Protein alignment was carried out using SIM alignment tool (ExPASy). Part of the conformation for compound 2 faces outside the active site into the solvent.
